How it started
History
The company commenced operations in 1988–89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterologicals, and cephalosporins, among others.
Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations, primarily from the U.S.
In 2014, Aurobindo purchased the generic operations of Actavis in seven Western European countries for US$41 million.
Business expansion
Aurobindo Pharma plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions like depot injections, inhalers, patches, and films. It has also set its sights on geographic expansion in new territories like Poland, Italy, Spain, Czech Republic, Portugal, and France, as the generic drug market in these countries is relatively small.
From Wikipedia’s article on Aurobindo Pharma, shared under CC BY-SA 4.0.2